ArticleFrontiers in immunology2026
Structural quality-tier assessment for TCR-pMHC functional enrichment.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
- AI-driven discovery in protein science for immunology and infectious disease research.Frontiers in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell receptor (TCR) recognition of peptide-MHC complexes (pMHCs) is central to adaptive immunity. Structural insights into TCR-pMHC interactions are critical for understanding antigen specificity and T-cell function. However, progress remains limited by the scarcity of experimentally resolved structures (275 TCR-pMHC class I structures in the PDB, Jan 2026). Although protein structure modelling tools have advanced rapidly, accurate structural modelling of TCRs remains challenging due to CDR loop hypervariability and conformational flexibility. In addition, there is a lack of reliable quality assessment strategies that do not rely on comparisons with experimental references. To address this, we benchmarked four general-purpose (AlphaFold2.3-Multimer, AlphaFold3, Boltz-2, Chai-1) and three TCR-specific (TCRmodel2, tFold-TCR, TCRdock) protein modelling algorithms by recalculating all experimentally determined TCR-pMHC class I complexes in the PDB. AlphaFold3 demonstrated superior performance across metrics (mean TCR-iRMSD = 3.59 Å and DockQ = 0.54), whereas the other algorithms displayed lower accuracy. Built on AlphaFold3 structures, we present a scalable and interpretable ML framework for the quality assessment of TCR-pMHC structural models without matched experimental references. We trained a random forest classifier integrating multiple confidence metrics (pLDDT, ipTM, ipSAE, iPAE, iPDE, pDockQv1-2) derived from 1325 modelled structures of 265 experimentally determined PDB TCR-pMHC class I complexes. The classifier reliably stratifies structural models into low-, acceptable-, medium-, and high-quality tiers defined by comparisons to their experimental reference structures, outperforming single metrics. These quality-tier predictions further enable the prioritization of high-confidence TCR-pMHC interactions. This was demonstrated across two held-out datasets comprising a total of 4,090 AlphaFold3-modelled TCR-pMHC complexes (20,450 models, 5 models per complex): a re-evaluated set of TCR-pMHC class I complexes from VDJdb (n = 606) and the reference IMMREP23 dataset (n = 3,484). We profiled the first dataset to reduce false-positive TCR-pMHC interactions erroneously annotated in VDJdb, and the second to enrich for biologically validated TCR-pMHC interactions amongst higher-quality structural models over their synthetic negative counterparts. Altogether, our structural quality-tier framework provides a scalable and interpretable approach that complements structural modelling and functional analyses of TCR-pMHC class I complexes, with direct translational applications in T-cell immunology and TCR-based immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.